Sotorasib
Amgen Unveils Exciting First-Line KRAS G12C NSCLC Data: Lumakras (Sotorasib) with Chemotherapy Shines at WCLC
Anika Sharma
Amgen has unveiled exciting findings from a segment of the CodeBreaK 101 clinical trial, a Phase 1b study investigating the ...
Results from Garsorasib Expand the Class of KRASG12C Inhibitors in NSCLC
SG Tylor
Early findings from the use of garsorasib (D-1553), an oral KRASG12C inhibitor, in patients with advanced non–small cell lung cancer ...
Sotorasib vs Docetaxel in KRAS G12C-Mutated NSCLC: ASCO 2023 Highlights
SG Tylor
ABSTRACT NUMBER – LBA9016 Amgen has made a courageous endeavor in cancer research over the last four decades by creating ...
